DrugBank ID	Drug Name	Target ID	Gene Symbol	UniProt ID	UniProt Entry	Regulation Type	PubMed IDs	Citations	Groups	Direct Classification	Detailed Classification	Categories	SMILES	PubChem ID	Pathways	Pathway Sources	KEGG Pathway IDs	DPD	PubChem Substance	KEGG Drug	PharmGKB	UniProtKB	TTD	Wikipedia	ChEMBL	RxCUI
DB00042	Botulinum toxin type B	BE0002138	SYT2	Q8N9I0	SYT2_HUMAN		17139284; 17016423; 19576489	"Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Poulain B, Lonchamp E, Jover E, Popoff MR, Molgo J: [Mechanisms of action of botulinum toxins and neurotoxins]. Ann Dermatol Venereol. 2009 May;136 Suppl 4:S73-6. doi: 10.1016/S0151-9638(09)74531-4."	Approved; Investigational	Peptides	"Organic Compounds; Organic Acids; Carboxylic Acids and Derivatives; Amino Acids, Peptides, and Analogues"	"Metalloendopeptidases; Agents that produce neuromuscular block (indirect); Enzymes and Coenzymes; Cholinergic Agents; Bacterial Proteins; Amino Acids, Peptides, and Proteins; Amphibian Venoms; Central Nervous System Depressants; Hydrolases; Muscle Relaxants; Toxins, Biological; Proteins; Membrane Transport Modulators; Enzymes; Acetylcholine Release Inhibitors; Musculo-Skeletal System; Biological Factors; Complex Mixtures; Bacterial Toxins; Metalloproteases; Neurotoxins; Botulinum Toxins; Peptide Hydrolases; Central Nervous System Agents; Neurotransmitter Agents; Ganglion Blockers; Venoms; Muscle Relaxants, Peripherally Acting Agents; Other Miscellaneous Therapeutic Agents; Endopeptidases; Anti-Dyskinesia Agents"						12854	46504750	D02735	PA164747061	P10844	DAP001272	Botulinum_toxin	CHEMBL1201569	860178
DB00619	Imatinib	BE0001124	DDR1	Q08345	DDR1_HUMAN	antagonist	15972446; 15994946; 16168515; 16298518; 16401709; 18938156	"Gotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C, Kajiguchi T, Ruan J, Lilleberg SL, Durocher JA, Lichy JH, Wang Y, Cohen PS, Arber DA, Heinrich MC, Neckers L, Galli SJ, Gilliland DG, Coutre SE: Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood. 2005 Oct 15;106(8):2865-70. Epub 2005 Jun 21.@@Xu L, Tong R, Cochran DM, Jain RK: Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res. 2005 Jul 1;65(13):5711-9.@@Neef M, Ledermann M, Saegesser H, Schneider V, Widmer N, Decosterd LA, Rochat B, Reichen J: Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term. J Hepatol. 2006 Jan;44(1):167-75. Epub 2005 Jul 12.@@Jubert C, Geoerger B, Grill J, Hartmann O, Vassal G: [Targeted therapies in pediatric oncology: a new therapeutic approach?]. Arch Pediatr. 2006 Feb;13(2):189-94. Epub 2005 Nov 17.@@Benjamin RS, Blanke CD, Blay JY, Bonvalot S, Eisenberg B: Management of gastrointestinal stromal tumors in the imatinib era: selected case studies. Oncologist. 2006 Jan;11(1):9-20.@@Day E, Waters B, Spiegel K, Alnadaf T, Manley PW, Buchdunger E, Walker C, Jarai G: Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol. 2008 Dec 3;599(1-3):44-53. doi: 10.1016/j.ejphar.2008.10.014. Epub 2008 Oct 11."	Approved	Benzanilides	Organic compounds; Benzenoids; Benzene and substituted derivatives; Anilides	Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strength unknown); Myelosuppressive Agents; Cancer immunotherapy; OCT2 Inhibitors; Enzyme Inhibitors; Piperazines; QTc Prolonging Agents; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP3A Substrates; UGT2B17 Inhibitors; Amides; Benzene Derivatives; Cytochrome P-450 CYP3A5 Inhibitors; Protein Kinase Inhibitors; Cytochrome P-450 CYP2C8 Substrates; OCT1 substrates; Immunotherapy; BCRP/ABCG2 Inhibitors; Cytochrome P-450 Substrates; Bcr-Abl Tyrosine Kinase Inhibitors; Cardiotoxic antineoplastic agents; Cytochrome P-450 Enzyme Inhibitors; Benzamides and benzamide derivatives; Cytochrome P-450 CYP3A Inhibitors; Photosensitizing Agents; P-glycoprotein substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Antineoplastic Agents; Cytochrome P-450 CYP2C19 Substrates; BCRP/ABCG2 Substrates; Kinase Inhibitor; Cytochrome P-450 CYP3A5 Substrates; P-glycoprotein inhibitors; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors (moderate); Drugs causing inadvertant photosensitivity; Tyrosine Kinase Inhibitors; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); BSEP/ABCB11 Substrates; Cytochrome P-450 CYP3A7 Inhibitors; UDP Glucuronosyltransferases Inhibitors; Immunosuppressive Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP2C9 Substrates; OATP1B3 substrates; Highest Risk QTc-Prolonging Agents; Pyrimidines; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 CYP1A2 Substrates	CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1		Imatinib Inhibition of BCR-ABL	drug_action		12429	46505055	D01441	PA10804		DNC001383	Imatinib	CHEMBL941	282388
DB12010	Fostamatinib	BE0001124	DDR1	Q08345	DDR1_HUMAN	inhibitor	26516587	"Rolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4."	Approved; Investigational	Methoxyanilines	Organic compounds; Benzenoids; Benzene and substituted derivatives; Aniline and substituted anilines	Amines; Cytochrome P-450 CYP3A Substrates; UGT1A1 Inhibitors; Pyridines; BCRP/ABCG2 Inhibitors; Cytochrome P-450 Substrates; Experimental Unapproved Treatments for COVID-19; Cytochrome P-450 Enzyme Inhibitors; Oxazines; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Kinase Inhibitor; Blood and Blood Forming Organs; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Hemostatics; Vasodilating Agents; Tyrosine Kinase Inhibitors; Cytochrome P-450 CYP3A4 Substrates; UGT1A9 Substrates; Phosphodiesterase 5 Inhibitors	COC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC					23528	347828328					Fostamatinib	CHEMBL2103830	2044896
DB15822	Pralsetinib	BE0001124	DDR1	Q08345	DDR1_HUMAN	inhibitor			Approved; Investigational			OATP1B1/SLCO1B1 Inhibitors; Cytochrome P-450 CYP3A Substrates; OAT1/SLC22A6 inhibitors; Cytochrome P-450 CYP3A5 Inhibitors; MATE 1 Inhibitors; Protein Kinase Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 Enzyme Inducers; BCRP/ABCG2 Inhibitors; Cytochrome P-450 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inducers; P-glycoprotein substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Antineoplastic Agents; BCRP/ABCG2 Substrates; Kinase Inhibitor; Cytochrome P-450 CYP2C8 Inducers; P-glycoprotein inhibitors; OATP1B3 inhibitors; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); MATE inhibitors; Rearranged during Transfection (RET) Inhibitors; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inducers (strength unknown); Antineoplastic and Immunomodulating Agents; MATE 2 Inhibitors; BSEP/ABCB11 Inhibitors; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 CYP1A2 Substrates	CO[C@@]1(CC[C@@H](CC1)C1=NC(NC2=NNC(C)=C2)=CC(C)=N1)C(=O)N[C@@H](C)C1=CC=C(N=C1)N1C=C(F)C=N1					23611						Pralsetinib	CHEMBL4582651	2394936